Detecting disease early for tomorrow’s health
Hummingbird Diagnostics is pioneering the development of novel miRNA-based liquid biopsy diagnostics for early disease detection of cancer, neurological, autoimmune and inflammatory diseases.
A powerful discovery engine generates biomarkers for diagnostics, drug discovery, treatment monitoring, and safety.
The privately held company is based in Heidelberg, Germany and Boston, USA.
Why we are doing what we are doing
From a multicenter study to the development of a miRNA-based liquid biopsy diagnostics.
See Hummingbird's story!
GOAL: FIND LINK BETWEEN DISEASES AND WHOLE BLOOD MIRNA
454 CLINICAL BLOOD SAMPLES 863 MIRNAS
CLINICALLY ROBUST PRE-ANALYTIC PROTOCOLS DEVELOPED
SPECIFIC MIRNA SIGNATURES IDENTIFIED IN MULTIPLE DISEASES
WHOLE BLOOD MIRNOME DISEASE DATABASE ESTABLISHED
RESULTS PUBLISHED IN NATURE METHODS, 2011
MIRNA-CANDIDATES FOR EARLY DIAGNOSIS & TREATMENT MONITORING DISCOVERED
IP SECURED UNMATCHED PATENT POSITION
VALIDATION STUDIES CONDUCTED
ON THE WAY TO A MIRNA-BASED DX TEST
Thinking different for tomorrow's health
Experienced leadership - motivated team - committed to delivering results
We are Hummingbird Diagnostics
Hummingbird's dedicated and experienced team is committed to delivering results. We will work with you from your first inquiry to the completion of your study to ensure that it is a success.
Our team has a proven track record in molecular diagnostics, genomic services, intellectual property, and bioinformatics.